A highly anticipated new immunotherapy from Merck & Co Inc proved effective in patients with advanced melanoma as well as some with lung cancer or head and neck cancer, according to early-stage studies presented on Monday. Merck filed in January for U.S. Food and Drug approval of MK3475, now known as pembrolizumab, as a treatment for melanoma, the deadliest form of skin cancer. But the drug's biggest sales opportunity is expected to be in treating lung cancer, which causes the most cancer deaths in the United States each year. The drug is part of an emerging class of medications that work by blocking a protein called PD-1, or Programmed Death receptor, used by cancer cells to evade the body's immune system. via Health News Headlines - Yahoo News Read More Here..
No comments:
Post a Comment